Details of the Drug Combination

General Information of Drug Combination (ID: DCMW0RW)

Drug Combination Name
Efaproxyn Ombrabulin
Indication
Disease Entry Status REF
Ewing sarcoma Investigative [1]
Component Drugs Efaproxyn   DMX7BM4 Ombrabulin   DM25HY3
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL
High-throughput Screening Result Testing Cell Line: TC-71
Zero Interaction Potency (ZIP) Score: 23.74
Bliss Independence Score: 28.356
Loewe Additivity Score: 6.263
LHighest Single Agent (HSA) Score: 10.742

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Efaproxyn
Disease Entry ICD 11 Status REF
Lung cancer 2C25.0 Phase 3 [2]
Efaproxyn Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Hemoglobin (HB) TTQO71U HBA_HUMAN Inhibitor [4]
------------------------------------------------------------------------------------
Indication(s) of Ombrabulin
Disease Entry ICD 11 Status REF
Sarcoma 2A60-2C35 Phase 3 [3]

References

1 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
2 ClinicalTrials.gov (NCT00083304) Whole Brain Radiation Therapy With Oxygen, With or Without RSR13, in Women With Brain Metastases From Breast Cancer. U.S. National Institutes of Health.
3 ClinicalTrials.gov (NCT00699517) A Study of AVE8062 in Advanced-stage Soft Tissue Sarcoma After Failure of Anthracycline and Ifosfamide Chemotherapies. U.S. National Institutes of Health.
4 Increased oxygenation of intracranial tumors by efaproxyn (efaproxiral), an allosteric hemoglobin modifier: In vivo EPR oximetry study. Int J Radiat Oncol Biol Phys. 2005 Apr 1;61(5):1503-9.